Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

LigBuilder 2: A Practical De Novo Drug Design Approach

LigBuilder V3: A Multi-Target De Novo Drug Design Approach.

LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design

Multiple Target Drug Design Using LigBuilder 3

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Structure-based <i>de novo</i> drug design using 3D deep generative models

Pocket v.2: further developments on receptor-based pharmacophore modeling.

Synthesis-driven design of 3D molecules for structure-based drug discovery using geometric transformers

Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets

Towards Structure-Based Protein Drug Design

Computational Design Of Ligand-Binding Proteins

Protein-protein interface analysis and hot spots identification for chemical ligand design.

De novo design of drug-binding proteins with predictable binding energy and specificity

AutoT&T v.2: An Efficient and Versatile Tool for Lead Structure Generation and Optimization.

SynthFormer: Equivariant Pharmacophore-based Generation of Molecules for Ligand-Based Drug Design

Learning to design drug-like molecules in three-dimensional space using deep generative models

Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation

Geometric Deep Learning for Structure-Based Ligand Design

Fragment-Based Ligand Generation Guided By Geometric Deep Learning On Protein-Ligand Structure

Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy.

A Practical Guide to Molecular Docking and Homology Modelling for Medicinal Chemists